Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (September 2024)
47 slides from Evogene's investor presentation, September 2024
Slide 1: Pioneering New Generation Life-Science Products
PIONEERING NEW GENERATION Life-Science Products OFER HAVIV | PRESIDENT & CEO September 2024
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding o
Slide 3: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial overview Annex II - Evogene subsidiaries 3
Slide 4: Our Vision
DECODING BIOLOGY OUR VISION PIONEER GROUNDBREAKING LIFE- SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS 4
Slide 5: Diverse Life-Science Industries
DIVERSE LIFE-SCIENCE INDUSTRIES MICROBES SMALL MOLECULES GENOMICS Microbials Therapeutic Crop Pharmaceuticals Medical for crops microbials protection Alternative Cannabis food Chemical Gene Food OD PHA stimulants OD PHA Advanced OD PHA therapy FO RM FO RM wound care FO RM & A & A Improved & A crops
Slide 6: The Complexity of Life Science Product Development
Pharma Ag-chemicals Industry Industry THE COMPLEXITY Cost of developing a single Years to develop a new crop pharmaceutical drug* protection product** OF LIFE SCIENCE 1995 8Y In the 1970’s PRODUCT $180M 2000 DEVELOPMENT 9Y Low probability of success 2005-2008 with high cost and long In recent years
Slide 7: The Resource Killer
THE RESOURCE KILLER LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS THE finding the winning candidates out of a vast number of possible prospects that CHALLENGE address a complex myriad of criteria, to reach higher success rate for products > DISCOVERY > OPTIMIZATION > DEVELOPMENT > REGULATION “Needle in th
Slide 8: Historic Singularity Point
TODAY WE ARE ON THE BRINK OF A HISTORIC BIG LIFE- SINGULARITY DATA SCIENCE AI POINT Computational technology advancements enable the LIFE-SCIENCE PRODUCT DEVELOPMENT discovery and optimization of the most promising candidates, addressing multiple development challenges towards successful life-scienc
Slide 9: Our Mission
OUR DECODING BIOLOGY MISSION WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING- EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS 9
Slide 10: When Life-Science Meets Disruptive Technologies
WHEN LIFE-SCIENCE MEETS DISRUPTIVE TECHNOLOGIES ISRAEL 2002 EVGN 129 30% 54% HQ Established NASDAQ Employees PhD’s Woman & TASE 3 4 COMMERCIAL Innovative AI Subsidiaries PRODUCTS* Tech Engines Bio-inoculant Castor varieties Microbes Genetic Elements Ag Biologicals Microbiome-based EVF701 Therapeutic
Slide 11: Commercial & Financial Partners
COMMERCIAL & Group FINANCIAL PARTNERS Investment & Investment & Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Collaboration Investment Collaboration 11
Slide 12: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial overview Annex II - Evogene subsidiaries 12
Slide 13: Lavie Bio Mission
MISSION Evogene’s Improve food quality, sustainability and agricultural productivity Subsidiary through microbiome-based, ag-biological products AG-BIOLOGICALS UNIQUE AI BROAD & STRATEGIC 2 REVENUE- A RAPIDLY TECH-PLATFORM DIVERSE INVESTORS & GENERATING GROWING AND DATA ASSETS PIPELINE PARTNERS GRAD
Slide 14: Yalos Bio-inoculant for cereal grains
Powered by Evogene’s Yalos® | Bio-inoculant for cereal grains* Subsidiary SOLD IN USA & CANADA** SUPERIOR PERFORMANCE CONSISTENT PERFORMANCE & expanding globally vs. alternatives 6% Check Yield improvement (%) 5% 4% 3% 2% 1% Other Ag-biologicals Control * Yalos® has regulatory approval in the US & C
Slide 15: MicroBoost AI Tech-Engine
MICROBOOST AI TECH-ENGINE Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Computational analysis of DB Powered by Experimental validation ▪ Commercial viability and optimization ~100,000 5% success ▪ Bacterial computational Bacterial teaming by function stra
Slide 16: LAV311 Bio-fungicide for fruit rots
Powered by Evogene’s LAV311 | Bio-fungicide for fruit rots Subsidiary Corteva to license Lavie Bio’s bio-fungicides LAV311 & LAV312 for fruit rots • Global exclusive license upon reaching diligence milestones • Deal terms: Future Royalties $5M upfront milestone from future payment payments sales Con
Slide 17: MicroBoost AI Tech-Engine
MICROBOOST AI TECH-ENGINE Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Computational analysis of DB Powered by Experimental validation 15% success ~100,000 Commercial viability and Bacterial optimization strains 250 Powered by Predicted bacterial strains
Slide 18: Casterra Mission
Mission Evogene’s Provide an integrated industrial-scale solution for castor cultivation, utilizing Subsidiary our elite seed varieties, for bio-based industries, with a focus on biofuels. CASTOR OIL - UNIQUE TECH INTEGRATED STRATEGIC COMMERCIAL EMERGING MARKET PLATFORM FOR AG-SOLUTION ALLIANCE PROD
Slide 19: Elite Castor Varieties & Orders
Powered by Evogene’s Elite Castor Varieties & Subsidiary 2023 Orders $2.2 Million $9.1 Million 19
Slide 20: 2024 New Seed Order & Seed Production Expansion
Powered by Evogene’s 2024 new seed order & Subsidiary seed production expansion ~$440K Production of approximately 500 tons 20
Slide 21: Generator AI Tech Engine
GENERATOR AI TECH ENGINE Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Breeding programs of varieties suitable for mechanized harvest Advanced genetic Powered by screening for high Genetic yield & oil traits diversity ~200 Powered by WW germplasm Field tri
Slide 22: Seed Production Operation, Aug 2024
Seed Production Operation, Aug 2024 Casterra completed a successful castor seed harvest in Brazil with shipments planned for Q3 2024 and began the harvest in Africa; Expecting to meet $8.4M in orders received in 2023 & 2024 Over 130 tons of our high-quality castor seeds ready for shipment from one o
Slide 23: Casterra Potential Next Stage
Powered by Evogene’s Casterra Potential Next Stage Subsidiary Potential next stage Biofuel Oil production to address growing market demands for castor oil as feedstock for biofuel and biobased industries Bio-based industries 23
Slide 24: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial overview Annex II - Evogene subsidiaries 24
Slide 25: Our Solution: Breakthrough Products
OUR SOLUTION Breakthrough Products Backed by Technology & Science PLATFORM SCIENCE Born from over a decade of intensive R&D, fueled by millions of dollars in investment, BIG DATA AI merging life-science with big- data and cutting-edge AI technology, the CPB directs and accelerates life-science produ
Slide 26: Discovery & Optimization
WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT DISCOVERY & OPTIMIZATION utilizing 3 dedicated AI tech-engines MICROBES The Result: Promising candidates addressing multiple development challenges towards successful SMALL life-science-based products. MOLECULES GENETIC PROBABILITY TIME COST ELEMENTS OF
Slide 27: AI Tech-Engines
AI TECH- ENGINES Discovery Direct & accelerate life-science product discovery & optimization Computational selection of the most promising candidates to initiate the product development process. Optimization Computational driven solution addressing optimization challenges for the selected candidates
Slide 28: AI Tech-Engine Dashboard (Example)
AI TECH-ENGINE DASHBOARD (Example) 28
Slide 29: Potential Markets for MicroBoost AI
Potential Markets for MicroBoost AI POTENTIAL (Example) MARKET DIVERSITY Microbials Therapeutic for crops microbials Food OD PHA Probiotics FO RM Structuring an & A RE ’ecosystem’ of diverse & AGRICULTU WE product types to be LLNESS Human & Dietary animal supplements probiotics developed utilizing o
Slide 30: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial overview Annex II - Evogene subsidiaries 30
Slide 31: A World of Opportunities for Our AI Tech Engines
A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES MICROBES SMALL MOLECULES GENETIC ELEMENTS Microbials Therapeutic Crop Pharmaceuticals Improved Medical for crops microbials protection crops Cannabis Chemical Advanced Alternative Gene Food OD PHA Probiotics stimulants OD PHA wound care food OD PHA th
Slide 32: Business Strategy
BUSINESS MAXIMUM STRATEGY POTENTIAL MINIMUM Capture the value of our AI tech-engines RISK through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial
Slide 33: Two Main Partnership Structures
BUSINESS MODEL Two Main Partnership Structures Capture the value of our AI tech-engines as product-development enablers, through: LICENSING COLLABORATION A time-limited license grant for utilizing Joint product development with a one of Evogene’s tech-engines, to a leading company utilizing related
Slide 34: Licensing
01 Business Model Licensing Potential revenue stream ▪ License fees & R&D reimbursements ▪ Royalties from sale of end-products ▪ Dividends to Evogene as a shareholder* ▪ Significant one-time-payment upon an exit event** Powered by *Subject to meeting the Israeli dividend tests and criteria. May no b
Slide 35: Collaboration
02 Business Model Collaboration Potential revenue stream ▪ Upfront payments ▪ R&D fees ▪ Milestone payments ▪ Royalties from sale of end-products Powered by 35
Slide 36: Licensing & Collaboration: Current Status
LICENSING & COLLABORATION | CURRENT STATUS Licensing Collaboration MICROBES SMALL MOLECULES GENETIC ELEMENTS Therapeutic microbials Crop protection Castor for bio-based industries • Immuno-oncology program • Herbicides • Elite castor seed varieties • GI related disorders • Fungicides • Insecticides
Slide 37: Agenda
AGENDA About Evogene Success Stories Value Proposition Business Strategy Summary Annex I - Financial overview Annex II - Evogene subsidiaries 37
Slide 38: Vision, Business Strategy, Mission
VISION BUSINESS STRATEGY Pioneer groundbreaking life-science MAXIMUM POTENTIAL, MINIMUM RISK products rooted in microbe, small molecule, and genomics innovations. EVOGENE PARTNER AI Tech Specific Engines Expertise MISSION Novel Life-Science PRODUCT We merge scientific expertise with cutting-edge AI
Slide 39: Thank You
THANK YOU
Slide 40: Annex I Financial Overview
Annex I FINANCIAL OVERVIEW 40
Slide 41: Key Financials: Balance Sheet
KEY FINANCIALS: BALANCE SHEET Thousands of US $ 30.06.2024 31.12.2023 Key Points: Current Assets 25,774 34,469 ▪ Consolidated cash position: ~$20.9 million as of 30.06.2024 Long-Term Assets 15,194 16,632 ▪ No bank debt Total Assets 40,968 51,101 Current Liabilities 5,893 6,944 Long-Term Liabilities
Slide 42: Key Financials: Income Statement
KEY FINANCIALS: BALANCE SHEET Thousands of US $ 1-6/2024 1-6/2023 Revenues 5,104 1,295 Key Points: Cost of revenues 847 783 ▪ H1 2024 revenue: $5.1M vs. $1.3M in H1 2023; anticipating continued growth in 2024. Gross profit 4,257 512 ▪ H1 2024 net loss: $9.8M vs. $14.8M in H1 Research and development
Slide 43: Annex II Evogene Subsidiaries
Annex II EVOGENE SUBSIDIARIES
Slide 44: Casterra Expected Value Drivers
Powered by Expected Value Drivers CASTOR OIL PRODUCTION Expanding the seed production operations in several CASTERRA’S MISSION: sites in Africa & Latin America, to fulfill all existing orders Provide an integrated industrial-scale solution for castor cultivation, utilizing our elite seed varieties,
Slide 45: Lavie Bio Expected Value Drivers
Powered by Expected Value Drivers Ag Biologicals BIO-PESTICIDES LAVIE BIO’S MISSION: Improve food quality, sustainability and LAV311 - US regulatory approval for bio-fungicide candidate for fruit rots – expected by 2024 agriculture productivity through microbiome based, AI-driven, ag-biological prod
Slide 46: Biomica Expected Value Drivers
Powered by Expected Value Drivers Human Microbiome BIOMICA’S MISSION: IMMUNO-ONCOLOGY Discovery and development of novel microbiome- Enrollment completion & Initial clinical readout of based therapeutics for human disorders, POC from first in-human study in 2024 utilizing cutting edge computational
Slide 47: AgPlenus Expected Value Drivers
Powered by Expected Value Drivers AG-CHEMICALS AGPLENUS’ MISSION: HERBICIDES Design next-generation, effective, and Corteva collaboration – Drive both projects towards sustainable crop protection products by next milestone leveraging predictive chemistry and biology Bayer collaboration - design addi